A prospective covid-19 cohort study of Jingyin granule in the treatment of mild and asymptomatic infections in patients with new crown pneumonia

Phase 1

• Conditions: covid-19

• Registration Number: ITMCTR2200005862
• Lead Sponsor: Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Age 18-60 years old (including 18 and 60 years old), regardless of gender;
(2) nucleic acid test results were positive, including New Coronavirus mild / asymptomatic infection.
(3) Voluntarily participate in the experiment and sign the written informed consent.

Exclusion Criteria

(1) Complicated with influenza, other pneumonia, suppurative tonsillitis, acute tracheobronchial inflammation, pulmonary tuberculosis, primary ciliary dyskinesia syndrome, and other acute nasal diseases (such as allergic rhinitis, acute and chronic rhinitis, acute and chronic sinusitis, etc.);
(2) During the course of the disease, he has received other oral drugs for the disease before treatment, such as cold drugs, antiviral drugs, antibiotics, traditional Chinese medicine and other drugs;
(3) Accompanied by gastrointestinal discomfort symptoms such as acute and chronic diarrhea;
(4) merge serious serious diseases such as heart, brain, lung, liver, kidney and blood system, such as viral hepatitis, hemophilia, diabetes mellitus, mental illness, etc.
(5) Pregnant or planned pregnant women, lactating women, patients of childbearing age who are unable or unwilling to take adequate contraception during the trial, or their spouses are unwilling to take contraception;
(6) Allergic constitution, such as a history of allergy to more than two drugs or foods, or known allergy to various components of the drug in this study;
(7) Participate in or are participating in clinical trials of other drugs within 3 months;
(8) Those who are unwilling to accept the intervention of traditional Chinese medicine;
(9) According to the judgment of the researcher, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as pregnancy, frequent changes in working environment, unstable living environment and other conditions that are easy to cause loss of follow-up.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ucleic acid negative conversion rate: the percentage of nucleic acid negative conversion of patients' nasopharyngeal swab at an interval of more than 24 hours;Conversion rate within 6 days: the percentage of mild / asymptomatic patients progressing to normal within 6 days;

Secondary Outcome Measures

Name	Time	Method
Mean time of negative conversion: from the first positive report of New Coronavirus nucleic acid test in Shanghai to the two negative interval of more than 24 hours interval in CDC.;Clinical symptom efficacy: refers to the disappearance rate and improvement rate of clinical symptoms before and after treatment;Average hospital stay: the average time of patients from entry to exit;